The immune-transcriptomic profiling of purified populations of CD14+ monocytes and CD2+ lymphocytes by next-generation RNA sequencing provides a unique look into the pathways that are up or down regulated in patients with aggressive prostate cancer as defined by adverse pathologic features compared to biopsy negative controls and men with indolent pathologic disease. This evidence concerns the gene CD14 and prostate cancer.